Exact Mass: 431.1634
Exact Mass Matches: 431.1634
Found 500 metabolites which its exact mass value is equals to given mass value 431.1634
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Glenvastatin
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites
SB 228357
SB228357 is a selective, potent and orall active 5-HT2C/2B receptor antagonist with pKi values of 6.9, 8.0 and 9.0 for 5-HT2A, 5-HT2B and 5-HT2C, respectively. SB228357 has antidepressant/anxiolytic effects[1][2].
Fusarin C
Fusarin C is produced by many Fusarium species in infected corn. Production by many Fusarium subspecies in infected corn. D009676 - Noxae > D009153 - Mutagens
Oxynarcotine
Oxynarcotine is an alkaloid from Papaver somniferum (opium poppy
Lafutidine
Lafutidine is a histamine H2-receptor antagonist that inhibits histamine-stimulated gastric acid secretion. Due to the resulting reduction in gastric volume and acidity, lafutidine can be used to treat ulcers and reflux. A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H2-receptor antagonists C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease[1].
Imidazo(5,1-F)(1,2,4)triazine, 4-(3-fluoro-1-azetidinyl)-7-methyl-5-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-
8-benzoyl-2-(1,2-dihydroxyhex-3-enyl)-9-hydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione
(3S,11R,11aR)-3-Methoxy-4,9-dimethyl-8beta-hydroxy-3beta-[[(2S,4S)-4-methyl-5-oxotetrahydrofuran]-2-yl]-2,3,5,6,7,8-hexahydrospiro[1H-cyclopenta[b]pyrrolo[1,2-a]azepine-11(10H),2(5H)-furan]-5,10-dione
4-methoxy-3-methyl-5-[(2Z,3aR)-3ac,10c-epoxy-1t-methyl-8t-((2S)-4c-methyl-5-oxo-tetrahydrofuran-2r-yl)-(3ar,10at,10bt)-decahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepin-2-ylidene]-5H-furan-2-one|oxyprotostemonine
Lafutidine
A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H2-receptor antagonists C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease[1].
C22H25NO8_8-Benzoyl-2-[(3Z)-1,2-dihydroxy-3-hexen-1-yl]-9-hydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione
C22H25NO8_1-Oxa-7-azaspiro[4.4]non-2-ene-4,6-dione, 8-benzoyl-2-[(1S,2S,3Z)-1,2-dihydroxy-3-hexen-1-yl]-9-hydroxy-8-methoxy-3-methyl-, (5S,8S,9R)
C22H25NO8_8-Benzoyl-2-[(3E)-1,2-dihydroxy-3-hexen-1-yl]-9-hydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione
(5S,8S)-8-benzoyl-2-[(Z,1S,2S)-1,2-dihydroxyhex-3-enyl]-9-hydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione
(5S,8S)-8-benzoyl-2-[(Z,1S,2S)-1,2-dihydroxyhex-3-enyl]-9-hydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione_major
Ala Asp Ile Asn
Ala Asp Leu Asn
Ala Asp Asn Ile
Ala Asp Asn Leu
Ala Asp Gln Val
Ala Asp Val Gln
Ala Glu Asn Val
Ala Glu Val Asn
Ala Ile Asp Asn
Ala Ile Asn Asp
Ala Leu Asp Asn
Ala Leu Asn Asp
Ala Met Asn Pro
Ala Met Pro Asn
Ala Asn Asp Ile
Ala Asn Asp Leu
Ala Asn Glu Val
Ala Asn Ile Asp
Ala Asn Leu Asp
Ala Asn Met Pro
Ala Asn Asn Asn
Ala Asn Pro Met
Ala Asn Val Glu
Ala Pro Met Asn
Ala Pro Asn Met
Ala Gln Asp Val
Ala Gln Val Asp
Ala Val Asp Gln
Ala Val Glu Asn
Ala Val Asn Glu
Ala Val Gln Asp
Cys Gly Pro Arg
Cys Gly Arg Pro
Cys Asn Pro Val
Cys Asn Val Pro
Cys Pro Gly Arg
Cys Pro Asn Val
Cys Pro Arg Gly
Cys Pro Val Asn
Cys Arg Gly Pro
Cys Arg Pro Gly
Cys Val Asn Pro
Cys Val Pro Asn
Asp Ala Ile Asn
Asp Ala Leu Asn
Asp Ala Asn Ile
Asp Ala Asn Leu
Asp Ala Gln Val
Asp Ala Val Gln
Asp Gly Ile Gln
Asp Gly Leu Gln
Asp Gly Gln Ile
Asp Gly Gln Leu
Asp Ile Ala Asn
Asp Ile Gly Gln
Asp Ile Asn Ala
Asp Ile Gln Gly
Asp Leu Ala Asn
Asp Leu Gly Gln
Asp Leu Asn Ala
Asp Leu Gln Gly
Asp Asn Ala Ile
Asp Asn Ala Leu
Asp Asn Ile Ala
Asp Asn Leu Ala
Asp Asn Pro Ser
Asp Asn Ser Pro
Asp Pro Asn Ser
Asp Pro Ser Asn
Asp Gln Ala Val
Asp Gln Gly Ile
Asp Gln Gly Leu
Asp Gln Ile Gly
Asp Gln Leu Gly
Asp Gln Val Ala
Asp Ser Asn Pro
Asp Ser Pro Asn
Asp Val Ala Gln
Asp Val Gln Ala
Glu Ala Asn Val
Glu Ala Val Asn
Glu Gly Ile Asn
Glu Gly Leu Asn
Glu Gly Asn Ile
Glu Gly Asn Leu
Glu Gly Gln Val
Glu Gly Val Gln
Glu Ile Gly Asn
Glu Ile Asn Gly
Glu Leu Gly Asn
Glu Leu Asn Gly
Glu Asn Ala Val
Glu Asn Gly Ile
Glu Asn Gly Leu
Glu Asn Ile Gly
Glu Asn Leu Gly
Glu Asn Val Ala
Glu Gln Gly Val
Glu Gln Val Gly
Glu Val Ala Asn
Glu Val Gly Gln
Glu Val Asn Ala
Glu Val Gln Gly
Gly Cys Pro Arg
Gly Cys Arg Pro
Gly Asp Ile Gln
Gly Asp Leu Gln
Gly Asp Gln Ile
Gly Asp Gln Leu
Gly Glu Ile Asn
Gly Glu Leu Asn
Gly Glu Asn Ile
Gly Glu Asn Leu
Gly Glu Gln Val
Gly Glu Val Gln
Gly Ile Asp Gln
Gly Ile Glu Asn
Gly Ile Asn Glu
Gly Ile Gln Asp
Gly Leu Asp Gln
Gly Leu Glu Asn
Gly Leu Asn Glu
Gly Leu Gln Asp
Gly Met Pro Gln
Gly Met Gln Pro
Gly Asn Glu Ile
Gly Asn Glu Leu
Gly Asn Ile Glu
Gly Asn Leu Glu
Gly Asn Asn Gln
Gly Asn Gln Asn
Gly Pro Cys Arg
Gly Pro Met Gln
Gly Pro Gln Met
Gly Pro Arg Cys
Gly Gln Asp Ile
Gly Gln Asp Leu
Gly Gln Glu Val
Gly Gln Ile Asp
Gly Gln Leu Asp
Gly Gln Met Pro
Gly Gln Asn Asn
Gly Gln Pro Met
Gly Gln Val Glu
Gly Arg Cys Pro
Gly Arg Pro Cys
Gly Val Glu Gln
Gly Val Gln Glu
Ile Ala Asp Asn
Ile Ala Asn Asp
Ile Asp Ala Asn
Ile Asp Gly Gln
Ile Asp Asn Ala
Ile Asp Gln Gly
Ile Glu Gly Asn
Ile Glu Asn Gly
Ile Gly Asp Gln
Ile Gly Glu Asn
Ile Gly Asn Glu
Ile Gly Gln Asp
Ile Asn Ala Asp
Ile Asn Asp Ala
Ile Asn Glu Gly
Ile Asn Gly Glu
Ile Gln Asp Gly
Ile Gln Gly Asp
Leu Ala Asp Asn
Leu Ala Asn Asp
Leu Asp Ala Asn
Leu Asp Gly Gln
Met Ala Asn Pro
Met Ala Pro Asn
Met Gly Pro Gln
Met Gly Gln Pro
Met Asn Ala Pro
Met Asn Pro Ala
Met Pro Ala Asn
Met Pro Gly Gln
Met Pro Asn Ala
Met Pro Gln Gly
Met Gln Gly Pro
Met Gln Pro Gly
Asn Ala Met Pro
Asn Ala Asn Asn
Asn Ala Pro Met
Asn Cys Pro Val
Asn Cys Val Pro
Asn Asp Pro Ser
Asn Asp Ser Pro
Asn Gly Asn Gln
Asn Gly Gln Asn
Asn Met Ala Pro
Asn Met Pro Ala
Asn Asn Ala Asn
Asn Asn Gly Gln
Asn Asn Asn Ala
Asn Asn Gln Gly
Asn Pro Ala Met
Asn Pro Cys Val
Asn Pro Asp Ser
Asn Pro Met Ala
Asn Pro Ser Asp
Asn Pro Val Cys
Asn Gln Gly Asn
Asn Gln Asn Gly
Asn Ser Asp Pro
Asn Ser Pro Asp
Asn Val Cys Pro
Asn Val Pro Cys
Pro Ala Met Asn
Pro Ala Asn Met
Pro Cys Gly Arg
Pro Cys Asn Val
Pro Cys Arg Gly
Pro Cys Val Asn
Pro Asp Asn Ser
Pro Asp Ser Asn
Pro Gly Cys Arg
Pro Gly Met Gln
Pro Gly Gln Met
Pro Gly Arg Cys
Pro Met Ala Asn
Pro Met Gly Gln
Pro Met Asn Ala
Pro Met Gln Gly
Pro Asn Ala Met
Pro Asn Cys Val
Pro Asn Asp Ser
Pro Asn Met Ala
Pro Asn Ser Asp
Pro Asn Val Cys
Pro Gln Gly Met
Pro Gln Met Gly
Pro Arg Cys Gly
Pro Arg Gly Cys
Pro Ser Asp Asn
Pro Ser Asn Asp
Pro Val Cys Asn
Pro Val Asn Cys
Gln Gly Met Pro
Gln Gly Asn Asn
Gln Gly Pro Met
Gln Met Gly Pro
Gln Met Pro Gly
Gln Asn Gly Asn
Gln Asn Asn Gly
Gln Pro Gly Met
Gln Pro Met Gly
Arg Cys Gly Pro
Arg Cys Pro Gly
Arg Gly Cys Pro
Arg Gly Pro Cys
Arg Pro Cys Gly
Arg Pro Gly Cys
Ser Asp Asn Pro
Ser Asp Pro Asn
Ser Asn Asp Pro
Ser Asn Pro Asp
Ser Pro Asp Asn
Ser Pro Asn Asp
Val Cys Asn Pro
Val Cys Pro Asn
Val Asn Cys Pro
Val Asn Pro Cys
Val Pro Cys Asn
Val Pro Asn Cys
Nornarceine
(Benzotriazol-1-Yloxy)Dipyrrolidinocarbenium Hexafluorophosphate
Tiodazosin
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
3-(4-Fluorobenzoyl)-2-(2-methyl-1-oxopropyl)-N,3-diphenyloxiranecarboxamide
Quinagolide hydrochloride
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists Quinagolide hydrochloride (CV205-502 hydrochloride) is a selective and orally active dopamine D2 receptor agonist. Quinagolide hydrochloride is an inhibitor of prolactin. Quinagolide hydrochloride down-regulates AKT levels and its phosphorylation. Quinagolide hydrochloride shows antitumor effects, it can be used for the research of cancer[1][2]. Quinagolide hydrochloride (CV205-502 hydrochloride) is a selective and orally active dopamine D2 receptor agonist. Quinagolide hydrochloride is an inhibitor of prolactin. Quinagolide hydrochloride down-regulates AKT levels and its phosphorylation. Quinagolide hydrochloride shows antitumor effects, it can be used for the research of cancer[1][2].
L-Octahydroindole-2-carboxylic acid benzyl ester 4-methylbenzenesulfonate
Ethaverine hydrochloride
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C471 - Enzyme Inhibitor > C667 - Monoamine Oxidase Inhibitor C93038 - Cation Channel Blocker
N4-(3-Chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazoline-4,6-diamine
1,3,5,2,4,6-Triazatriphosphorine,2,2,4,4,6-pentakis(1-aziridinyl)-2,2,4,4,6,6-hexahydro-6-(4-morpholinyl)- (9CI)
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-threonine phenylmethyl ester
(R)-Benzyl-2-[4-(trifluoromethyl)phenyl]-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazolium Tetrafluoroborate
5-O-(2-AZIDO-2-DEOXY-BETA-D-MANNOPYRANOSYL)-URIDINE
Succinimidyl (2R)-6-(Tetrahydro-2H-pyran-2-yloxy)-2,5,7,8-tetramethylchroman-2-carboxylate
sodium,1-dodecoxy-4-(2-hydroxyethylamino)-1,4-dioxobutane-2-sulfonate
(1S)-1-(2-(Difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine
2-Methyl-3-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-5-(trifluoromethyl)quinazolin-4-one
1-((3R,4R)-3-(((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)-4-methoxypyrrolidin-1-yl)prop-2-en-1-one
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Guanosine, 2-deoxy-6-O-ethyl-2-fluoro-2-methyl-, cyclic 3,5-(1-methylethyl (R)-phosphate), (2R)-
Xanomeline tartrate
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010277 - Parasympathomimetics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018679 - Cholinergic Agonists C78272 - Agent Affecting Nervous System > C47796 - Cholinergic Agonist D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs Xanomeline (LY 246708) is the potent agonist of muscarinic M1/M4 receptor with antipsychotic-like activity. Xanomeline (LY 246708) increases neuronal excitability. Xanomeline (LY 246708) can be used for the research of schizophrenia[1][2][3].
Esreboxetine succinate
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C185721 - Norepinephrine Reuptake Inhibitor C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
1-benzyl-N-(2-morpholinoethyl)-4-oxo-1,4-dihydropyrido[1,2-a]pyrrolo[2,3-d]pyrimidine-2-carboxamide
5-{[1-(2,3-Dichlorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine
2-Mercapto-N-[1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[A]heptalen-7-YL]acetamide
Oxynarcotine
(2E,4E)-5-[(1R,7S,8S,9R)-7-acetyloxy-4-methoxycarbonyl-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoate
pseurotin A
A spirocyclic that is 1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione bearing 1,2-dihydroxyhex-3-en-1-yl, methyl, methoxy, benzoyl and hydroxy substituents at positions 2, 3, 8, 8 and 9 respectively.
N2,N5-Bis(3-acetamidophenyl)pyridine-2,5-dicarboxamide
(5Z)-4-methoxy-3-methyl-5-[(1R,6S,8R,9R,10R,11S)-11-methyl-6-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-13,14-dioxa-5-azatetracyclo[6.5.1.01,10.05,9]tetradecan-12-ylidene]furan-2-one
8-benzoyl-2-[(Z)-1,2-dihydroxyhex-3-enyl]-9-hydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione
2-[1-(4-tert-butylphenyl)sulfonyl-4-piperidinyl]-6-chloro-1H-benzimidazole
6-{[2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl]thio}-1-(4-methylphenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
5-(3,4-dimethoxyphenyl)-3-(2-furanylmethyl)-4-imino-5H-[1]benzopyrano[2,3-d]pyrimidin-8-ol
1-[4-[2-(3-Chlorophenyl)-5-phenyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]ethanone
3-Furanyl-[4-[2-(3-methoxyphenyl)-5,6-dimethyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]methanone
1-Methyl-6-[(4-methyl-1-piperidinyl)sulfonyl]-3-[oxo(1-piperidinyl)methyl]-4-quinolinone
3-Furanyl-[4-[2-(4-methoxyphenyl)-5,6-dimethyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]methanone
1-(4-Methoxy-2-nitrophenyl)-4-(5,6,7,8-tetrahydronaphthalen-2-ylsulfonyl)piperazine
1-methyl-N-(2-methylcyclohexyl)-4-oxo-6-(1-pyrrolidinylsulfonyl)-3-quinolinecarboxamide
N-[4-(diethylsulfamoyl)phenyl]-4-(4-morpholinylmethyl)benzamide
3,4,5-trimethoxy-N-[[2-(4-morpholinyl)anilino]-sulfanylidenemethyl]benzamide
4-Tert-butylbenzoic acid [2-[(2-methoxy-3-dibenzofuranyl)amino]-2-oxoethyl] ester
(4-Methylphenyl)-[4-[4-nitro-3-(3-pyridinylmethylamino)phenyl]-1-piperazinyl]methanone
(E)-3-[2-(azepan-1-yl)-9-methyl-4-oxopyrido[1,2-a]pyrimidin-3-yl]-2-cyano-N-(furan-2-ylmethyl)prop-2-enamide
2,5-diethoxy-N-[2-(2-methylphenyl)ethyl]-4-(1-tetrazolyl)benzenesulfonamide
(3R)-2-acetyl-N-ethyl-3-(2-hydroxyethyl)-4-[3-(5-pyrimidinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
(3S)-2-acetyl-N-ethyl-3-(2-hydroxyethyl)-4-[3-(5-pyrimidinyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
18-(2-Methoxyphenyl)-15-phenyl-11-oxa-13,15-diazatetracyclo[8.8.0.02,7.012,17]octadeca-1(10),2,4,6,8,12(17),13-heptaen-16-imine
(1S,9R,10R,11R)-10-(hydroxymethyl)-N,N-dimethyl-12-(3-methylphenyl)sulfonyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
18-(3-Methoxyphenyl)-15-phenyl-11-oxa-13,15-diazatetracyclo[8.8.0.02,7.012,17]octadeca-1(10),2,4,6,8,12(17),13-heptaen-16-imine
N-[(4-chlorophenyl)methyl]-2-[(3S,5Z,8S,12S)-8-methyl-2,9-dioxo-1,10-diazabicyclo[10.3.0]pentadec-5-en-3-yl]acetamide
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1S)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1R)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1S)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-6-oxo-7-phenyl-1-(2-pyridinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
1-[(3aS,4R,9bR)-8-(2-fluorophenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-(2-pyridinyl)ethanone
1-[(3aS,4R,9bR)-8-(3-fluorophenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-(3-pyridinyl)ethanone
1-[(3aR,4S,9bS)-8-(3-fluorophenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-(3-pyridinyl)ethanone
(6R,7R,8S)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8R)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(1R,9S,10S,11S)-10-(hydroxymethyl)-N,N-dimethyl-12-(3-methylphenyl)sulfonyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1R)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-6-oxo-7-phenyl-1-(2-pyridinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
1-[(3aR,4R,9bS)-8-(2-fluorophenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-(2-pyridinyl)ethanone
1-[(3aR,4R,9bS)-8-(3-fluorophenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-(3-pyridinyl)ethanone
1-[(3aS,4S,9bR)-8-(3-fluorophenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-(3-pyridinyl)ethanone
(6R,7S,8S)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8S)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8S)-7-[4-(2-fluorophenyl)phenyl]-8-(hydroxymethyl)-4-[oxo(3-pyridinyl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
3beta-Chloro-N,N-bis(2-chloroethyl)-androst-5-en-17beta-amine
(1R,2S)-2-benzoyl-8-[(Z,1S,2S)-1,2-dihydroxyhex-3-enyl]-1-hydroxy-2-methoxy-7-methyl-9-oxa-3-azaspiro[4.4]non-7-ene-4,6-dione
CM037
CM037 is a selective inhibitor of ALDH1A1 (aldehyde dehydrogenase 1A1) with an IC50 of 4.6 μM[1].
GLX351322
GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM.
NVP 231
NVP 231 is a potent, specific, and reversible ceramide kinase (CerK) inhibitor(IC50=12 nM) that competitively inhibits binding of ceramide to CerK[1]. NVP 231 induces cell apoptosis by increasing DNA fragmentation and caspase-3 and caspase-9 cleavage[2].